This study was published in Diabetes Care 2006 Jul;29(7):1478-85
Study title and authors:
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH, d'Emden M, Smilde JG, Pocock SJ.
Harborview Medical Center, 325 Ninth Ave., #359720, Seattle, WA 98104-2499, USA. rhknopp@u.washington.edu
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16801565.1
The purpose of the study was to assess the effect of 10 mg of atorvastatin versus placebo in subjects with type 2 diabetes and low LDL cholesterol levels. The study lasted four years and included 2,410 subjects who were assigned to receive 10 mg of atorvastatin or placebo.
The study found that those who were assigned atorvastatin had a 6% increased risk of death compared to those who were assigned placebo.
The data from this study shows that atorvastatin is associated with an increased death rate in patients who have type 2 diabetes.
Links to other studies:
Statins increase the risk of diabetes by 48%
Statin therapy associated with a 9% increased risk for diabetes
Statin treatment increases cardiovascular diseases in diabetics by 31%
